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reserve assessed by a dipyridamole infusion using
2D-strain echocardiography: the impact of
diabetes and age, and the prognostic value
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Pierre Massabuau2,3, Isabelle Berry1,5 and Olivier Lairez1,2,3Abstract
Aims: Although dipyridamole is a widely used pharmacological stress agent, the direct effects on myocardium are
not entirely known. Diabetic cardiomyopathy can be investigated by 2D-strain echocardiography. The aim of this
study was to assess myocardial functional reserve after dipyridamole infusion using speckle-tracking
echocardiography.
Methods: Seventy-five patients referred for dipyridamole stress myocardial perfusion gated SPECT (MPGS) were
examined by echocardiography to assess a new concept of longitudinal strain reserve (LSR) and longitudinal strain
rate reserve (LSRR) respectively defined by the differences of global longitudinal strain (GLS) and longitudinal strain
rate between peak stress after dipyridamole and rest. Twelve patients with myocardial ischemia were excluded on
the basis of MPGS as gold standard.
Results: Mean LSR was −2.28±2.19% and was more important in the 28 (44%) diabetic patients (−3.27±1.93%;
p = 0.001). After multivariate analyses, only diabetes improved LSR (p = 0.011) after dipyridamole infusion and was
not associated with glycaemic control (p = 0.21), insulin therapy (p = 0.46) or duration of the disease (p = 0.80).
Conversely, age (p = 0.002) remained associated with a decrease in LSR. LSSR was also correlated to age (p = 0.005).
Patients with a LSR < 0% have a better survival after 15 months (log-rank p = 0.0012).
Conclusion: LSR explored by 2D speckle-tracking echocardiography after dipyridamole infusion is a simple and
new concept that provides new insights into the impact of diabetes and age on the myocardium with a potential
prognostic value.
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Dipyridamole is a widely used pharmacological agent to
test coronary reserve in patients referred for stress myo-
cardial perfusion imaging. The mechanism of stress with
dipyridamole implies a coronary vasodilatation, which
leads to the detection of myocardial ischemia through* Correspondence: thomascognet31@gmail.com
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reproduction in any medium, provided the orcoronary steal phenomena. Dipyridamole mainly in-
creases the flow supply in the subendocardial layer by
decreasing vascular resistance [1], but the resulting ef-
fects on myocardium and especially on myocardial strain
have not been explored yet. The myocardial functional
reserve between peak stress and rest reflects the ability
of the myocardium to improve its function during stress
testing. Stress testing is recommended in order to detect
myocardial ischemia [2], but the role of the myocardial
functional reserve during stress remains undervalued
even if it provides important information in someLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thyroidism [3,4]. At the same time, the ability of two-
dimensional (2D) strain echocardiography to precisely
assess myocardial function provides new possibilities for
an accurate measurement of the myocardial function re-
serve in stress conditions [5,6] and especially in diabetes
in which longitudinal strain is altered at baseline [7]. Ac-
tually, diabetic patients have early myocardial damage at
baseline that requires to be detected by means of mod-
ern tools such as biomarkers and imaging [8].
The aim of this study was to assess the effects of di-
pyridamole on the myocardium in a population of pa-
tients referred for myocardial perfusion imaging by
gated single-photon emission computed tomography
(MPGS) and to explore the myocardial functional re-
serve with dipyridamole by means of a longitudinal
strain reserve with speckle-tracking echocardiography.
Methods
Study population
Patients referred for MPGS with previous or non-coronary
artery disease (CAD) and without history of myocardial
infarction were prospectively included from March to
September 2011. All patients underwent a complete phys-
ical exam before inclusion. Exclusion criteria were docu-
mented allergies to dipyridamole, asthma, systolic blood
pressure < 90 mmHg, decompensated heart failure or
acute angina, significant valvular disease, hypertrophic car-
diomyopathy, atrial fibrillation and the possibility to in-
duce stress by effort. All patients were informed of the
study design and agreed to the protocol before inclusion.
Patients with identified MPGS ischemia were also ex-
cluded of the analysis.
Dipyridamole testing and MPGS protocols
All enrolled patients underwent MPGS with intravenous
dipyridamole pharmacologic stress using the standard-
ized protocols from the European Association of Nuclear
Medicine / European Society of Cardiology guidelines
[9]. Caffeinated beverages, foods and medications, and
medications containing methylxanthine were avoided for
at least 12 hours prior to stress testing. Dipyridamole
was given as a continuous infusion intravenously at 0.6
mg/kg over the course of 4 minutes. Arterial pressure
was recorded before infusion, every 2 minutes during
stress and also at the peak of dipyridamole effects (8 mi-
nutes). Stress MPGS was performed for all patients with
a weight-adjusted dose of 300–400 MBq of 99mTc-
tetrofosmin injected 3 minutes after the completion of
the dipyridamole infusion. MPGS was acquired 15 to 30
minutes after a radiotracer injection using a Symbia T6
(Siemens Healthcare, Erlangen, Germany) double-headed
gamma camera equipped with low-energy, high-resolution
collimators. Data was acquired for 180° with 64 frames of30 and 20 second durations at stress and at rest, respect-
ively; a 64 × 64 matrix; 8-frame gating; and a 20% window
centred on the 140-keV photo peak of Tc-99m. Rest
MPGS was performed only if stress MPGS was considered
as pathological, with a 2-fold-higher dose of 99mTc-
tetrofosmin injected at least 3 hours after the stress test-
ing. All patients underwent low-dose CT using a Symbia
T6 system (Siemens Healthcare, Erlangen, Germany) for
attenuation correction (130 keV, 30 to 45 mAs).
Echocardiographic protocol
Echocardiography for all patients was performed at rest
and 3 minutes after the completion of the dipyridamole
infusion, i.e. at peak of stress, with a Imagic KM 60
(Kontron Medical, Saint-Germain en Laye, France) using
a 2.5 MHz transducer. A complete two-dimensional grey
scale echocardiography including the three standard ap-
ical views (four, three and two chambers) with a frame
rate > 75 frame/s was performed for each patient. Left
ventricle ejection fraction (LVEF) and volumes were
assessed before and after the dipyridamole infusion as
diastolic parameters. Myocardial strain was measured
using speckle-tracking echocardiography.
Data analysis and interpretation
The 17-segments model, as defined by the American Soci-
ety of Echocardiography, was used to examine both echo-
cardiography and MPGS [10]. The apex segment was then
excluded for the analysis.
For the echocardiography, digital data of 3 consecutive
heart cycles were recorded and transferred to a personal
computer with My Lab Desk workstation (Kontron Med-
ical, Saint-Germain en Laye, France) for offline analysis.
The endocardial border was defined manually in end sys-
tole and automatically tracked frame by frame. Operator
assessed optimal evaluation of both quality of tracking and
region of interest. Global longitudinal strain (GLS) was
obtained by averaging all segmental longitudinal strain
curves computed from the conventional apical two-,
three- and four-chamber views. Longitudinal strain re-
serve (LSR) was defined by the difference between peak
systolic global longitudinal strain at the peak of vasodilata-
tion with dipyridamole and at rest. The longitudinal strain
rate was determined for the left ventricle as the maximal
strain rate value (calculated as the temporal derivative of
strain) during the ejection phase. The longitudinal strain
rate reserve (LSRR) was similarly obtained (Figure 1). Left
ventricular ejection fraction (LVEF) was assessed by trans-
thoracic echocardiography using the conventional apical
two- and four-chamber views and the modified Simpson’s
method.
For MPGS studies, off-line analysis was performed on
Syngo MI Applications software (Siemens Healthcare,
Erlangen, Germany). The images were assessed visually
Figure 1 Schematic representation of global longitudinal strain (GLS) curves (Panel A) and longitudinal strain rate curves (Panel B)
focused of the systolic phase of the cardiac cycle. Improvement of longitudinal strain reserve (negative LSR) and longitudinal strain rate
reserve (negative LSRR) in green curves and decrease of LSR and LSRR (positive LSR and LSRR) in red curves both after dipyridamole infusion as
compared to baseline values (black curves).
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server interpreted echocardiographic and MPGS studies.
Myocardial ischemia was defined by at least one reversible
myocardial perfusion defect between stress and rest myo-
cardial perfusion gated-SPECT and was expressed by the
number of segments affected.
Follow up
Data about the occurrence of adverse events were
obtained from medical records by direct patients’ inter-
views or from the referring physician. The primary end
point was defined by all-cause mortality. Patients unable
to be interviewed up to 6 months at the date of follow-
up were considered as lost to follow-up.
Statistical analysis
Data were expressed as mean +/− SD. Nominal values
were expressed as numbers and percentages. Normality
was tested by the Kolmogorov-Smirnov test. The associ-
ation between the mean values of continuous normally
distributed variables were compared using unpaired and
paired Student’s t test and the Mann–Whitney rank sum
test was used when the samples were not normally dis-
tributed or had unequal variances. Comparison between
multiple groups was performed with a variance analysis
(ANOVA). Nominal variables were investigated by the χ2
test. Linear regression analysis was used to investigate
the relation between LSR-LSRR and variables. Conven-
tional variables correlated with LSR with a p value <
0.05 at first univariate analyses were used to build thefinal multivariate stepwise model. Receiver operating char-
acteristic (ROC) curves were computed to determine opti-
mal cut-off point for longitudinal strain reserve as well as
to calculate area under the curve (AUC) to determine
prognostic significance. Multivariate Cox regression model
was built to identify echocardiographic parameters as-
sociated with all-cause mortality. Survival curve was de-
termined according to the Kaplan-Meier method, and
cumulative event rates compared by means of the log-
rank test. Differences were considered statistically signifi-
cant for p-values of < 0.05. All analyses were performed
on SPSS software version 20 (SPSS Inc., Chicago, Illinois).
Results
Population
Eighty patients were prospectively included. Four pa-
tients (5%) were excluded from the analysis due to a
poor resolution of 2D echocardiography as a conse-
quence of poor ultrasonic window (obesity or pulmonary
disease) that did not allow speckle-tracking imaging and
1 (<1%) due to refusal of gated-SPECT after echocardi-
ography. Among the 75 other patients included, 12 were
excluded for MPGS ischemia with at least one or more
reversible defect segment (Figure 2). Male represented
59% of the 63 patients finally enrolled in the study. The
mean age was 70 ± 11 years with a median age of 71
ranging from 46 to 90 years old. Twenty-six patients
(41%) had a previous history of coronary artery disease
and 28 (44%) suffered from diabetes. Diabetes lasted less
than five years in 10/28 patients. Thirty-nine patients
Figure 2 Flow chart of the study population. MPGS = Myocardial perfusion imaging by gated single-photon emission computed tomography.
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was 51±14%. Baseline characteristics are presented in
Table 1.
Blood pressure and heart rate during stress
Hemodynamic during dipyridamole infusions and echo-
cardiographic examinations remained unchanged for all
patients. The decrease of systolic blood pressure with di-
pyridamole after stress testing was not only insignificant
for the whole population (136±22 at rest vs. 130±21
mmHg after dipyridamole infusion, p = 0.14) but the
diabetic patients in comparison to the non-diabetics also
showed a non-significant variation of systolic blood pres-
sure (−3.8±12.4 vs. -2.9±31.6 mmHg; p = 0.88, respect-
ively). Results are similar regarding the diastolic blood
pressure (p = 0.09). The mean heart rate increased from
70±14 beats/min at rest to 80±18 beats/min after the di-
pyridamole infusion (p < 0.001) showing the pharmaco-
logical effect of dipyridamole. No examination had to be
stopped for safety reasons.
Effects of dipyridamole on strain reserve
The effects of dipyridamole on LSR according to base-
line characteristics, coronary risk factors, dyspnea and
medications are presented in Table 2. In our general
population, the mean GLS before dipyridamole infusionwas −14.5±4.2% and reached −16.8±4.5% at the max-
imum effect of vasodilatation. Consequently, the mean
LSR was −2.28±2.19%. LSR did not depend on systolic
blood pressure (p = 0.99), diastolic blood pressure (p =
0.57) or heart rate (p = 0.85) changes during stress, as
LSRR with p-values of 0.89, 0.57 and 0.17, respectively
for systolic blood pressure, diastolic blood pressure and
heart rate.
By univariate analysis, only age was associated with a
decrease of LSR after dipyridamole infusion whereas
patients with diabetes, higher Body Mass Index (BMI)
and current smoking showed an improvement of LSR
(Table 3). Increasing age was significantly correlated to a
decrease of LSR (p < 0.0001) as presented in Figure 3.
As shown in Table 4, no difference was observed be-
tween diabetic and non-diabetic patients for GLS before
stress (−13.9±3.7 vs. -15.0±4.5%; p = 0.30) and after the
dipyridamole infusion (−17.2±4.2 vs. -16.5±4.8%; p =
0.55) but LSR was higher in the diabetic population
(−3.27±1.93 vs. -1.49±2.08%; p = 0.001). Moreover, GLS
of diabetic increased significantly by 24% in stress condi-
tions (p = 0.003). Among the 28 patients with diabetes,
22 of them presented also overweight, defined as a BMI
> 25 kg/m2 (p < 0.004). GLS before dipyridamole infu-
sion was not different between patients with or without
overweight (−14.2±3.6 vs. -15.0±4.9%; p = 0.43) but LSR
Table 1 Baseline characteristics
Variable All patients (n=63) Diabetic (n=28) Non-diabetic (n=35) p-value
Age (yrs) 70 ±11 70±10 72±10 0.04
Male (%) 37 (59) 18 (64) 19 (54) 0.42
BMI (kg/m2) 26.3 ± 3.9 28.1±4.0 24.8±3.2 0.001
SBP (mmHg) 137 ± 21 135±16 138±24 0.55
DBP (mmHg) 76±11 75±12 77±11 0.64
HR (beats/min) 70 ± 14 69±12 71±16 0.59
Dyspnea status (%)
NYHA I 12 (19) 7 (25) 5 (14) 0.83
NYHA II 39 (62) 16 (57) 23 (66) 0.65
NYHA III 12 (19) 5 (18) 7 (20) 0.72
Coronary risk factors (%)
Hypertension 45 (71) 19 (48) 26 (71) 0.58
Current smoking 27 (43) 12 (43) 15 (43) 0.99
Hypercholesterolemia 32 (51) 14 (50) 18 (51) 0.91
Family history of cardiovascular 4 (6) 2 (7) 2 (5) 0.82
disease
Previous coronary artery disease (%) 26 (41) 11 (39) 15 (43) 0.78
Medications (%)
ACE inhibitors/ARB 38 (62) 16 (57) 22 (63) 0.44
Beta-blockers 30 (48) 12 (43) 18 (51) 0.50
Calcium antagonists 25 (40) 10 (36) 15 (43) 0.56
Diabetic characteristics
Duration of diabetes (yrs) - 12.0±8.8 - -
HbA1c (%) - 7.0±2.4 - -
Insulin therapy (%) - 20 (71) - -
Oral therapy (%) 12 (43)
Metformin therapy (%) - 8 (29) - -
Retinopathy (%) - 11 (39) - -
Peripheral arterial disease (%) - 15 (54) - -
Supra aortic - 6 (21) - -
Lower limb - 11 (39) - -
Values are presented as n (%) or mean +/− SD.
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; ACE = angiotensin-converting enzyme; ARB = angiotensin
receptor blocker; LVEF = left ventricle ejection fraction; LVEDV and LVESV = left ventricle end diastolic and end systolic volume.
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(−2.83±1.85 vs. -1.50±2.42%; p = 0.016). After a mul-
tivariate analysis, only age (p = 0.001) remained inde-
pendently associated with a decrease of LSR after the
dipyridamole infusion. Conversely, LSR remained signifi-
cantly improved only in diabetic patients (p = 0.008).
Among all echocardiographic parameters at baseline and
after stress, including systolic, diastolic, hemodynamic
and speckle-tracking parameters, only LSR was modified
according to the diabetic status (Table 4). LSR was not
correlated to the duration of diabetes (p = 0.80) or
HbA1c level (p = 0.21) and was not influenced bydedicated treatments especially insulin therapy (p =
0.46), the presence of retinopathy (p = 0.43) or periph-
eral vascular disease (p = 0.34).
LSRR was only associated with aging (p = 0.005) and
was not influenced by diabetes (p = 0.57). Moreover, lon-
gitudinal strain rate increased by 16% between baseline
and peak stress in the diabetic population (p = 0.11).
Prognosis and follow-up
During a mean follow-up of 15±5 months, 6 (10%) pa-
tients reached the primary endpoint. Only one patient
was lost to follow-up and was excluded for survival
Table 2 Effects of dipyridamole on longitudinal strain
reserve
Coef. 95% for LSR
p-value
Baseline characteristics
Age (yrs) * −0.49 <0.0001
Male † −2.45 0.46
Female −2.04
BMI (kg/m2) * 0.25 0.045
Dyspnea status †
NYHA I −2.33 0.98
NYHA II −2.30
NYHA III −2.17





Current smoking −2.92 0.045
No current smoking −1.80
Hypercholesterolemia −2.29 0.98
No hypercholesterolemia −2.27
Family history of cardiovascular disease −0.90 0.19
No family history of cardiovascular disease −2.38




ACE inhibitors/ARB −2.50 0.44
No ACE inhibitors/ARB −2.07
Beta-blockers −1.80 0.10
No beta-blockers −2.72
Calcium antagonists −2.00 0.41
No calcium antagonists −2.47
LSR = longitudinal strain reserve; BMI = body mass index; ACE = angiotensin-
converting enzyme; ARB = angiotensin receptor blocker.
*: Spearman correlation.
†: ANOVA.
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tricle end systolic volume at stress (HR: 1.047 [95% C.I:
1.018 – 1.075]; p = 0.001; Table 5), the difference of left
ventricle end systolic volumes between stress and rest
(HR: 1.065 [95% C.I: 1.019 – 1.113]; p = 0.005) and a
positive LSR (HR: 15.493 [95% C.I: 1.419 – 169.182]; p =
0.025) remained independently associated with all-cause
mortality. ROC curve analysis in Figure 4 identified posi-
tive LSR (cut-off value of 0%) as a predictor of all-cause
mortality with a sensitivity of 89% and a specificity of 50%,
for an area under the curve of AUC = 0.79 (p = 0.021).The Kaplan-Meier analysis showed better survival in pa-
tients with a negative LSR (log-rank p = 0.012). All cause-
mortality in the diabetic population was associated with a
lower LSR (−0.59±1.17 vs. -3.60±1.77%; p = 0.028) but
prognosis was not significantly better in the diabetic popu-
lation compared to the non-diabetic since they have a bet-
ter LSR (p = 0.102 vs. p = 0.446).
Discussion
LSR assessed with dipyridamole, defined by the differ-
ence between GLS after and before a dipyridamole infu-
sion, is a new concept of myocardial functional reserve.
Our study shows a LSR increase in patients with dia-
betes that decreases with aging with a potential interest
in prognosis evaluation.
2D-strain echocardiography with speckle-tracking im-
aging enables a general analysis of the left ventricle at rest
or during stress [11]. Regional analysis during MPGS and
perfusion echocardiography with dipyridamole are com-
plementary for the assessment of CAD [12] but for the
first time, we are reporting the effects of dipyridamole on
global longitudinal strain by means of 2D-speckle tracking
echocardiography. This study highlights a new concept of
LSR during stress with dipyridamole. Palmieri and al. pre-
viously experienced a myocardial reserve by means of
Doppler tissue imaging. Despite different pharmacological
effects, low doses of dobutamine in patients with type 1
diabetes have similar effects, compared to dipyridamole in
our study, by improving both global longitudinal strain
and longitudinal strain rate of at least 29% [13].
Different deformation modalities such as longitudinal
strain [14,15] or torsion [16-18] can be modified by left
ventricular load but even if dipyridamole has several sys-
temic effects that can lead to hemodynamic changes
[19], we show that there are no blood pressure impacts
or heart rate variations on LSR.
After a multivariate analysis, only aging is associated
with a decrease of LSR during stress with dipyridamole.
This result is consistent with the consequences of aging
on myocardial deformation at rest: global longitudinal
strain declines at rest with aging in a healthy population
[20], especially in basal segments [21]. Consistent results
were also found with longitudinal strain rate in baseline
[22]. These results could be partly explained by a re-
duced coronary flow reserve with aging [23] as described
with myocardial ischemia [24]. Therefore, LSR may re-
flect the physiological age of the myocardium.
Conversely, diabetes is associated with an increase in
LSR whereas GLS before the dipyridamole infusion in
the diabetic patients is lower but not statistically differ-
ent than non-diabetic patients. These results at baseline
are different from the studies of Ernande et al. in which
GLS was impaired at rest in patients with diabetes [25],
even sometimes before diastolic dysfunction [26]. This
Table 3 Univariate and multivariate linear regression model for longitudinal strain reserve
Multivariate analysis
Coef. [95% CI] p-value Coef. [95% CI] p-value
Age −0.10 [−0.14 – -0.05] <0.0001 −0.08 [−0.13 – -0.04] 0.001
Gender (Male) 0.42 [−0.71 – 1.54] 0.46
BMI 0.14 [0.01 – 0.28] 0.045
Hypertension 0.18 [−1.05 – 1.41] 0,77
Diabetic 1.79 [0.77 – 2.81] 0.001 1.33 [0.36 – 2.30] 0.008
Current smoking 1.11 [0.02 – 2.20] 0.045
Hypercholesterolemia 0.02 [−1.09 – 1.13] 0.98
Family history of cardiovascular disease −1.48 [−3.72 – 0.77] 0.19
ACE inhibitors/ARB 0.44 [−0.70 – 1.57] 0.44
Beta-blockers −0.92 [−2.01 – 0.17] 0.10
Calcium antagonists −0.47 [−1.60 – 0.66] 0.41
Previous CAD −0.44 [−1.57 – 0.68] 0.43
BMI = body mass index; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; MPGS = myocardial perfusion gated SPECT; CAD = coronary
artery disease.
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cent description of impaired coronary microvascular
function in type 2 diabetic patients without CAD [27].
Our smaller population of diabetic patients and a popu-
lation partly composed of patients with previous CAD
might explain this difference. Several studies confirm the
endothelial dysfunction secondary to diabetes [28] butFigure 3 Impact of age on LSR and LSRR A. Correlation between increas
longitudinal strain reserve, LSRR = longitudinal strain rate reserve.we show, for the first time, the mechanic consequences of
this endothelial dysfunction in diabetic patients, which
lead to an exacerbated response to arterial vasodilatation
induced by dipyridamole. These results are consistent with
the hemodynamic findings of Picchi and al. who previ-
ously described an increased basal coronary blood flow at
rest in diabetes as a cause of decreased coronary flowing age and decreased longitudinal strain rate reserve in Panel B. LSR =
Table 4 Echocardiographic parameters according to diabetic status
Echocardiographic parameters All patients (n=63) Diabetic (n=28) Non-diabetic (n=35) p-value
Rest
LVEF (%) 50.7±14.4 49.8±13.0 51.4±15.5 0.66
EDV (ml) 103.7±46.9 106.7±46.6 101.2±47.6 0.65
ESV (ml) 53.7±39.4 56.6±36.7 51.3±41.8 0.60
TVI LVOT (cm) 22.7±6.0 19.3±5.0 19.3±5.5 0.96
GLS (%) −14.5±4.2 −13.9±3.7 −15.0±4.5 0.30
Longitudinal Strain rate (s-1) −1.19±0.35 −1.15±0.26 −1.22±0.40 0.43
E (cm.s-1) 77±25 78±26 75±25 0.60
A (cm.s-1) 81±29 79±28 82±29 0.77
E/A (cm.s-1) 1.07±0.58 1.14±0.57 1.01±0.59 0.41
DT (s) 205±86 197±88 210±85 0.56
Stress
LVEF (%) 54.6±13.9 54.3±14.0 54.9±13.9 0.89
EDV (ml) 98.8±41.6 98.8±36.3 98.9±45.9 0.99
ESV (ml) 48.8±35.6 48.6±31.6 48.9±38.9 0.97
TVI LVOT (cm) 22.7±6.0 23.0±5.0 22.5±6.8 0.76
GLS (%) −16.8±4.5 −17.2±4.2 −16.5±4.8 0.55
Longitudinal Strain rate (s-1) −1.34±0.44 −1.33±0.52 −1.35±0.37 0.86
E (cm.s-1) 84±23 83±23 85±23 0.75
A (cm.s-1) 89±33 88±32 89±35 0.85
E/A (cm.s-1) 1.13±0.77 1.15±0.61 1.10±0.89 0.83
DT (s) 179±73 177±76 180±71 0.87
Δ (stress – rest)
Δ LVEF (%) 3.9±8.4 4.6±9.8 3.5±7.2 0.60
Δ EDV (ml) −4.8±25.3 −7.9±30.0 −2.3±20.9 0.39
Δ ESV (ml) −4.9±20.5 −8.0±24.1 −2.4±17.0 0.28
Δ TVI LVOT (cm) 3.4±2.5 3.7±2.6 3.2±2.3 0.39
LSR (%) −2.28±2.19 −3.27±1.93 −1.49±2.08 0.001
LSRR (s-1) −0.15±0.34 −0.17±0.43 −0.12±0.26 0.57
LVEF = left ventricle ejection fraction; EDV = end diastolic volume; ESV = end systolic volume, TVI LVOT = time-velocity integral in the left ventricular outflow tract,
GLS = global longitudinal strain; DT = mitral deceleration time, LSR = longitudinal strain reserve; LSRR = longitudinal strain rate reserve.
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with GLS, coronary blood flow is not altered after ad-
enosine in the diabetic group compared to the non-
diabetic group [29]. The lack of any decrease in systolic
or diastolic blood pressure in the diabetic group might
also explain these results. Actually, reduced myocardial
perfusion with vasodilatator in diabetic patient is asso-
ciated with a significant decrease in blood pressure, a
consequence of autonomic neuropathy [30]. Coronary
metabolic vasodilatation mainly depends on both nitric
oxide metabolism, which is impaired in diabetic pa-
tients [31], and on adenosine pathways. The predo-
minant vasodilatation effects of dipyridamole through
A2A-adenosine receptors, which are increased in the
hearts of diabetic rats, [32] could explain the increaseof LSR in the diabetic population. LSR is not influenced
by duration of diabetes in contrast to baseline [33]. Gly-
caemic control, treatments and vascular disease other
than CAD do not influence either LSR. In parallel, left
ventricular diastolic function is impaired precociously
in patients with insulin resistance and glucose metabol-
ism disorders even without overt diabetes [34] but the
diastolic functional reserve defined by Jellis et al. is
not altered by diabetes during effort conditions [35].
Diabetes seems to alter first the contractile function as
described with dobutamine stress echocardiography
[36] while myocardial perfusion seems to be main-
tained [37]. This hypothesis may explain the improve-
ment of the LSR in diabetic patients. As a result, LSR
appears to be an interesting and sensitive tool to
Table 5 Echocardiographic parameters associated with all-cause mortality in a multivariate Cox regression model
Univariate analysis Multivariate analysis
HR [95% CI] p-value HR [95% CI] p-value
Rest
LVEF (%) 0.889 [0.821 - 0.964] 0.004
EDV (ml) 1.019 [1.007 - 1.031] 0.002
ESV (ml) 1.020 [1.007 - 1.033] 0.002
GLS (%) 1.335 [1.091 – 1.633] 0.005
Stress
LVEF (%) 0.898 [0.839 - 0.960] 0.002
EDV (ml) 1.026 [1.012 - 1.040] <0.0001
ESV (ml) 1.034 [1.017 - 1.051] <0.0001 1.047 [1.018 - 1.075] 0.001
GLS (%) 1.481 [1.155 - 1.899] 0.002
Δ (stress – rest)
Δ LVEF (%) 0.962 [0.874 - 1.059] 0.430
Δ EDV (ml) 1.003 [0.970 - 1.037] 0.862
Δ ESV (ml) 1.044 [1.006 - 1.084] 0.022 1.065 [1.019 - 1.113] 0.005
LSR (%) 1.395 [0.973 – 2.001] 0.070
LSR > 0 6.012 [1.211 - 29.856] 0.028 15.493 [1.419 - 169.182] 0.025
LVEF = left ventricle ejection fraction; EDV = end diastolic volume; ESV = end systolic volume, TVI LVOT = time-velocity integral in the left ventricular outflow tract,
GLS = global longitudinal strain; LSR = longitudinal strain reserve; LSRR = longitudinal strain rate reserve.
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invasively, regardless of the characteristics of the
diabetes.
Strain rate is load dependent and reflects the regional
difference in contractility [38]. In our study, LSRR is not
influenced by hemodynamic changes induced by dipyrid-
amole. Therefore, LSRR reflects changes in contractility
due to myocardial injury only. Moreover, in diabetes, the
stability of longitudinal strain rate with stress and theFigure 4 Prognostic value of LSR A. Kaplan-Meier curve representing the
longitudinal strain reserve. AUC = area under the curve, Se = sensitivity andinsignificant increase in LSRR between diabetic and non-
diabetic patients results in a homogeneous and stable re-
gional contractility. This may be the consequence of an
overall and homogeneous myocardial injury. Because
subendocardial longitudinal fibres are the most vulnerable
in pathological conditions, we deliberately focused our
analysis on longitudinal deformation [39]. Longitudinal
strain is the most reliable and studied parameter of de-
formation modalities and the comparison of radial strainimpact of a positive LSR on all-cause mortality in Panel B. LSR =
Spe = specitivity.
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ent studies [25,40].
A positive LSR that reflects lack of myocardial func-
tional reserve after dipyridamole infusion appears prom-
ising to predict all-cause mortality in a population of
patients referred for MPGS even when ischemia is ex-
cluded. The cut-off value of 0% of LSR is easy to meas-
ure and allows therefore a rapid and reliable evaluation
in routine clinical practice.
However, our study has several limitations. First, pres-
ence of autonomic neuropathy [41] but also abdominal
visceral adipose tissue [42], and the evaluation of aortic
stiffness [43] or oxidative stress [44], all associated with
myocardial function impairment, could have provided
important information. In parallel, our population of
diabetic patients is to small to define subset groups
according to glycaemic control that could influence evo-
lution of LSR and LSRR during follow up. Unfortunately,
ischemia cannot be ruled out with certainty and there-
fore might interfere with our results. MPGS is an effi-
cient and validated exam to assess ischemia and CAD
and even if patients with at least only one reversible de-
fect segment were excluded, pluritroncular patients
could lead to false negative tests. Moreover, coronary
angiography should have been interesting to differentiate
respective impacts of epicardial coronary artery disease
and microvascular dysfunction on strain reserve among
patients with diabetes.
Finally, further prospective studies are necessary to de-
fine the interaction between diabetes and LSR and a po-
tential prognostic value in diabetic patients. The use of
the selective adenosine A2A receptor agonist vasodilator
stress agent could be interesting in this context [45].
However, the present results suggest that addition of
LSR to dipyridamole stress myocardial contrast perfu-
sion echocardiography could improve its prognostic
value [46].Conclusion
LSR assessed after a dipyridamole infusion is a new con-
cept of stress examination using speckle-tracking im-
aging. LSR increases in the diabetic population and
warrants special attention for examinations in the eld-
erly population. Myocardial function reserve assessed
by LSR after dipyridamole with speckle-tracking echo-
cardiography may be of interest for the evaluation of
both prognosis and impact of co-morbidities.Consent
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